<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325350</url>
  </required_header>
  <id_info>
    <org_study_id>192024-058</org_study_id>
    <secondary_id>2011-000380-27</secondary_id>
    <nct_id>NCT01325350</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared
      with vehicle and over-the-counter (OTC) minoxidil 2% solution in women with female pattern
      hair loss. All treatments will be provided in a double-blinded fashion except for minoxidil
      2% solution which will be provided open-label.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Target Area Hair Count (TAHC)</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters squared (cm^2). A positive change from Baseline indicated improvement (increase in the number of terminal hairs). A negative change from Baseline indicated worsening (decrease in the number of terminal hairs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>The SSA score measured scalp hair growth. Using a 7-point scale, participants answered the Question: &quot;Since the start of the study, the amount of my hair has?&quot;: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>The investigator compared the participant's scalp hair growth at Month 6 to a photograph of the scalp taken at Baseline and using the 7-point IGA score, the investigator answered the question: &quot;Since the start of the study, the amount of the subject's hair has?&quot;: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>At the completion of the study, 3 independent dermatologists using the 7-point GPR score compared photographs of the participant's scalp hair growth at Month 6 to Baseline and answered the question: &quot;Compared with the baseline image, the amount of the subject's hair has?&quot;: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Target Area Hair Width (TAHW)</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Digital imaging analysis was used to measure TAHW in millimeters/centimeters squared (mm/cm^2). The diameters of all terminal hairs (individual hairs ≥ 30 microns) in the target area were summed and reported together. A positive change from Baseline indicated improvement (increase in the diameter of terminal hairs). A negative change from Baseline indicated worsening (decrease in the diameter of terminal hairs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Target Area Hair Darkness (TAHD)</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>Digital imaging analysis was used to measure TAHD. The darkness of all terminal hairs (individual hairs ≥ 30 microns) in the target area were summed and divided by total number of terminal hairs in the same target area and was reported as intensity units. A positive change from Baseline indicated improvement (increase in the darkness of terminal hairs).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Alopecia</condition>
  <condition>Baldness</condition>
  <arm_group>
    <arm_group_label>bimatoprost Formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bimatoprost Formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bimatoprost Formulation C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bimatoprost vehicle solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>minoxidil 2% solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost Formulation A</intervention_name>
    <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
    <arm_group_label>bimatoprost Formulation A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost Formulation B</intervention_name>
    <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
    <arm_group_label>bimatoprost Formulation B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost Formulation C</intervention_name>
    <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
    <arm_group_label>bimatoprost Formulation C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimatoprost vehicle solution</intervention_name>
    <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
    <arm_group_label>bimatoprost vehicle solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>minoxidil 2% solution</intervention_name>
    <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.</description>
    <arm_group_label>minoxidil 2% solution</arm_group_label>
    <other_name>Rogaine®</other_name>
    <other_name>Regaine®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate female pattern hair loss with ongoing hair loss for at least 1 year

          -  Willingness to have micro-dot-tattoo applied to scalp

          -  Willingness to maintain same hair style, length and hair color during study

        Exclusion Criteria:

          -  Drug or alcohol abuse within 12 months

          -  HIV positive

          -  Received hair transplants or had scalp reductions

          -  Use of hair weaves, hair extensions or wigs within 3 months

          -  Oral or topical minoxidil treatment within 6 months

          -  Application of topical steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) to
             scalp within 4 weeks
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <results_first_submitted>March 3, 2014</results_first_submitted>
  <results_first_submitted_qc>March 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2014</results_first_posted>
  <disposition_first_submitted>July 31, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 31, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 7, 2013</disposition_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Minoxidil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bimatoprost Formulation A</title>
          <description>Approximately one milliliter (mL) of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Bimatoprost Formulation B</title>
          <description>Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
        </group>
        <group group_id="P3">
          <title>Bimatoprost Formulation C</title>
          <description>Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
        </group>
        <group group_id="P4">
          <title>Vehicle to Bimatoprost</title>
          <description>Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
        </group>
        <group group_id="P5">
          <title>Minoxidil 2% Solution</title>
          <description>Approximately one mL of minoxidil 2% solution applied evenly onto pre-specified area on scalp, twice daily for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="61"/>
                <participants group_id="P5" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Receive Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bimatoprost Formulation A</title>
          <description>Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Bimatoprost Formulation B</title>
          <description>Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Bimatoprost Formulation C</title>
          <description>Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
        </group>
        <group group_id="B4">
          <title>Vehicle to Bimatoprost</title>
          <description>Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
        </group>
        <group group_id="B5">
          <title>Minoxidil 2% Solution</title>
          <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="61"/>
            <count group_id="B4" value="61"/>
            <count group_id="B5" value="62"/>
            <count group_id="B6" value="306"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 34 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35 to 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="48"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="62"/>
                    <measurement group_id="B6" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Target Area Hair Count (TAHC)</title>
        <description>TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters squared (cm^2). A positive change from Baseline indicated improvement (increase in the number of terminal hairs). A negative change from Baseline indicated worsening (decrease in the number of terminal hairs).</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost Formulation A</title>
            <description>Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost Formulation B</title>
            <description>Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Bimatoprost Formulation C</title>
            <description>Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle to Bimatoprost</title>
            <description>Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Minoxidil 2% Solution</title>
            <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Target Area Hair Count (TAHC)</title>
          <description>TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters squared (cm^2). A positive change from Baseline indicated improvement (increase in the number of terminal hairs). A negative change from Baseline indicated worsening (decrease in the number of terminal hairs).</description>
          <population>Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.</population>
          <units>terminal hairs/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.1" spread="54.78"/>
                    <measurement group_id="O2" value="161.1" spread="63.85"/>
                    <measurement group_id="O3" value="145.2" spread="63.42"/>
                    <measurement group_id="O4" value="163.0" spread="57.28"/>
                    <measurement group_id="O5" value="156.3" spread="55.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="17.10"/>
                    <measurement group_id="O2" value="-3.5" spread="18.21"/>
                    <measurement group_id="O3" value="4.3" spread="16.82"/>
                    <measurement group_id="O4" value="1.1" spread="20.44"/>
                    <measurement group_id="O5" value="13.6" spread="18.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score</title>
        <description>The SSA score measured scalp hair growth. Using a 7-point scale, participants answered the Question: &quot;Since the start of the study, the amount of my hair has?&quot;: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost Formulation A</title>
            <description>Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost Formulation B</title>
            <description>Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Bimatoprost Formulation C</title>
            <description>Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle to Bimatoprost</title>
            <description>Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Minoxidil 2% Solution</title>
            <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) Score</title>
          <description>The SSA score measured scalp hair growth. Using a 7-point scale, participants answered the Question: &quot;Since the start of the study, the amount of my hair has?&quot;: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.</description>
          <population>Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Greatly Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="9.3"/>
                    <measurement group_id="O4" value="3.3"/>
                    <measurement group_id="O5" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="18.0"/>
                    <measurement group_id="O5" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="21.7"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="24.6"/>
                    <measurement group_id="O5" value="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remained the Same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="29.5"/>
                    <measurement group_id="O5" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="11.7"/>
                    <measurement group_id="O3" value="13.0"/>
                    <measurement group_id="O4" value="13.1"/>
                    <measurement group_id="O5" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="8.2"/>
                    <measurement group_id="O5" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greatly Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.3"/>
                    <measurement group_id="O5" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score</title>
        <description>The investigator compared the participant's scalp hair growth at Month 6 to a photograph of the scalp taken at Baseline and using the 7-point IGA score, the investigator answered the question: &quot;Since the start of the study, the amount of the subject’s hair has?&quot;: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost Formulation A</title>
            <description>Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost Formulation B</title>
            <description>Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Bimatoprost Formulation C</title>
            <description>Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle to Bimatoprost</title>
            <description>Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Minoxidil 2% Solution</title>
            <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Each Response Category of the Investigator Global Assessment (IGA) Score</title>
          <description>The investigator compared the participant's scalp hair growth at Month 6 to a photograph of the scalp taken at Baseline and using the 7-point IGA score, the investigator answered the question: &quot;Since the start of the study, the amount of the subject’s hair has?&quot;: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.</description>
          <population>Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Greatly Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="7.4"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="14.8"/>
                    <measurement group_id="O5" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="35.0"/>
                    <measurement group_id="O3" value="25.9"/>
                    <measurement group_id="O4" value="23.0"/>
                    <measurement group_id="O5" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remained the Same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="51.9"/>
                    <measurement group_id="O4" value="54.1"/>
                    <measurement group_id="O5" value="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="3.7"/>
                    <measurement group_id="O4" value="6.6"/>
                    <measurement group_id="O5" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="1.7"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greatly Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score</title>
        <description>At the completion of the study, 3 independent dermatologists using the 7-point GPR score compared photographs of the participant's scalp hair growth at Month 6 to Baseline and answered the question: &quot;Compared with the baseline image, the amount of the subject’s hair has?&quot;: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost Formulation A</title>
            <description>Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost Formulation B</title>
            <description>Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Bimatoprost Formulation C</title>
            <description>Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle to Bimatoprost</title>
            <description>Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Minoxidil 2% Solution</title>
            <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Each Response Category of the Global Panel Review (GPR) Score</title>
          <description>At the completion of the study, 3 independent dermatologists using the 7-point GPR score compared photographs of the participant's scalp hair growth at Month 6 to Baseline and answered the question: &quot;Compared with the baseline image, the amount of the subject’s hair has?&quot;: Greatly Increased, Moderately Increased, Slightly Increased, Remained the Same, Slightly Decreased, Moderately Decreased or Greatly Decreased. The percentage of participants in each response category is presented.</description>
          <population>Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Greatly Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.1"/>
                    <measurement group_id="O4" value="1.6"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="6.8"/>
                    <measurement group_id="O3" value="6.3"/>
                    <measurement group_id="O4" value="6.6"/>
                    <measurement group_id="O5" value="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remained the Same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3"/>
                    <measurement group_id="O2" value="81.4"/>
                    <measurement group_id="O3" value="81.3"/>
                    <measurement group_id="O4" value="88.5"/>
                    <measurement group_id="O5" value="79.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slightly Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="11.9"/>
                    <measurement group_id="O3" value="10.4"/>
                    <measurement group_id="O4" value="3.3"/>
                    <measurement group_id="O5" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderately Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greatly Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Target Area Hair Width (TAHW)</title>
        <description>Digital imaging analysis was used to measure TAHW in millimeters/centimeters squared (mm/cm^2). The diameters of all terminal hairs (individual hairs ≥ 30 microns) in the target area were summed and reported together. A positive change from Baseline indicated improvement (increase in the diameter of terminal hairs). A negative change from Baseline indicated worsening (decrease in the diameter of terminal hairs).</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost Formulation A</title>
            <description>Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost Formulation B</title>
            <description>Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Bimatoprost Formulation C</title>
            <description>Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle to Bimatoprost</title>
            <description>Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Minoxidil 2% Solution</title>
            <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Target Area Hair Width (TAHW)</title>
          <description>Digital imaging analysis was used to measure TAHW in millimeters/centimeters squared (mm/cm^2). The diameters of all terminal hairs (individual hairs ≥ 30 microns) in the target area were summed and reported together. A positive change from Baseline indicated improvement (increase in the diameter of terminal hairs). A negative change from Baseline indicated worsening (decrease in the diameter of terminal hairs).</description>
          <population>Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.</population>
          <units>mm/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.92" spread="3.444"/>
                    <measurement group_id="O2" value="9.64" spread="3.308"/>
                    <measurement group_id="O3" value="8.86" spread="3.977"/>
                    <measurement group_id="O4" value="10.13" spread="4.165"/>
                    <measurement group_id="O5" value="9.76" spread="3.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline from Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="1.198"/>
                    <measurement group_id="O2" value="-0.19" spread="1.067"/>
                    <measurement group_id="O3" value="0.30" spread="1.263"/>
                    <measurement group_id="O4" value="0.07" spread="1.183"/>
                    <measurement group_id="O5" value="0.87" spread="1.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Target Area Hair Darkness (TAHD)</title>
        <description>Digital imaging analysis was used to measure TAHD. The darkness of all terminal hairs (individual hairs ≥ 30 microns) in the target area were summed and divided by total number of terminal hairs in the same target area and was reported as intensity units. A positive change from Baseline indicated improvement (increase in the darkness of terminal hairs).</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Bimatoprost Formulation A</title>
            <description>Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Bimatoprost Formulation B</title>
            <description>Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Bimatoprost Formulation C</title>
            <description>Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle to Bimatoprost</title>
            <description>Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Minoxidil 2% Solution</title>
            <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Target Area Hair Darkness (TAHD)</title>
          <description>Digital imaging analysis was used to measure TAHD. The darkness of all terminal hairs (individual hairs ≥ 30 microns) in the target area were summed and divided by total number of terminal hairs in the same target area and was reported as intensity units. A positive change from Baseline indicated improvement (increase in the darkness of terminal hairs).</description>
          <population>Participants from the Modified Intent-to-Treat Population (all randomized participants who received treatment and had both Baseline and post-Baseline measurements) who had data available for this outcome measure.</population>
          <units>Intensity units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="61"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.63" spread="23.837"/>
                    <measurement group_id="O2" value="100.12" spread="25.077"/>
                    <measurement group_id="O3" value="92.76" spread="19.433"/>
                    <measurement group_id="O4" value="96.90" spread="22.678"/>
                    <measurement group_id="O5" value="93.07" spread="20.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" spread="13.084"/>
                    <measurement group_id="O2" value="4.22" spread="13.159"/>
                    <measurement group_id="O3" value="2.11" spread="14.674"/>
                    <measurement group_id="O4" value="2.07" spread="11.486"/>
                    <measurement group_id="O5" value="2.12" spread="11.561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Safety Population (all participants who received at least 1 dose of study treatment) was used to calculate the number of participants at risk for treatment-emergent Serious Adverse Events and treatment-emergent Adverse Events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bimatoprost Formulation A</title>
          <description>Approximately one mL of bimatoprost Formulation A applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Bimatoprost Formulation B</title>
          <description>Approximately one mL of bimatoprost Formulation B applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
        </group>
        <group group_id="E3">
          <title>Bimatoprost Formulation C</title>
          <description>Approximately one mL of bimatoprost Formulation C applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
        </group>
        <group group_id="E4">
          <title>Vehicle to Bimatoprost</title>
          <description>Approximately one mL of vehicle to bimatoprost applied evenly onto pre-specified area on scalp, once daily for 6 months.</description>
        </group>
        <group group_id="E5">
          <title>Minoxidil 2% Solution</title>
          <description>Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Event not treatment-related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <description>Event not treatment-related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <description>Event not treatment-related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <description>Event not treatment-related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <description>Events not treatment-related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Event not treatment-related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <description>Event not treatment-related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <description>Events not treatment-related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <description>Event not treatment-related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <description>Event not treatment-related</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Event not treatment-related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <description>Event not treatment-related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pruritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertrichosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

